| Bid | 1.64 |
| Market Cap | 323.14M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.11 |
| PE Ratio (ttm) | -15.82 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.75 |
| Volume | 1,700,810 |
| Avg. Volume (20D) | 1,580,596 |
| Open | 1.71 |
| Previous Close | 1.67 |
| Day's Range | 1.69 - 1.78 |
| 52-Week Range | 1.38 - 2.59 |
| Beta | undefined |
About CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed t...
Analyst Forecast
According to 3 analyst ratings, the average rating for CERS stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 72.41% from the latest price.
Next Earnings Release
Analysts project revenue of $50.69M, reflecting a 8.39% YoY growth and earnings per share of -0.01, making a 0.00% YoY.
2 months ago · businesswire.com
Cerus Corporation Announces Third Quarter 2024 Financial ResultsCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended September 30, 2024. Total revenue for the three and nin...
2 months ago · businesswire.com
Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual MeetingCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) A...
